CEO SUMMARY: Medicare’s decision to cease covering many pharmacogenomic tests puts as many as 19 million Americans who have genetic variations affecting their response to medications at risk. These medications are commonly prescribed for patients with cardiovascular disease, pain, depression, anxiety, and cancer. Meanwhile, medical centers such as Mayo Clinic are conducting clinical studies to collect evidence that appropriate use of pharmacogenomic tests can improve patient outcomes while also reducing the cost of care.
Medicare Ends Coverage for Genetic Drug-Sensitivity Tests
New Precision Medicine Initiative now put on hold?
- By Joseph Burns
- > From the Volume XXII NO. 9 - June 22, 2015 Issue
- Tags: aco, clinical lab, clinical laboratories, cpt, cpt 81225, electronic health record, electronic health record system, FDA Clearance, gene test, genetic test, genetic testing, genetic testing for, genetic tests, genome project, genomic testing, genomics, hie, human genome, human genome project, impac, laboratories, laboratory medicine, local coverage determination, medical lab, medical laboratories, medical records, Medicare, Medicare Administrative Contractor, personalized medicine, pharmacogenetic, pharmacogenetics, pharmacogenomic tests, pharmacogenomics, the human genome project
